Emil D. Kakkis - 14 Oct 2021 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
President & CEO, Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
14 Oct 2021
Net transactions value
-$69,093
Form type
4
Filing time
18 Oct 2021, 18:44:19 UTC
Previous filing
10 May 2021
Next filing
01 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Tax liability $69,093 -853 -0.14% $81.00 594,347 14 Oct 2021 Direct F1, F2
holding RARE Common Stock 2,259,741 14 Oct 2021 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.